SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Thorek Daniel L J)
 

Sökning: WFRF:(Thorek Daniel L J) > (2017) > In vivo immuno-targ...

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)

Pankov, Dmitry (författare)
Memorial Sloan-Kettering Cancer Center
Sjöström, Ludvig (författare)
Memorial Sloan-Kettering Cancer Center,Lund University
Kalidindi, Teja (författare)
Memorial Sloan-Kettering Cancer Center
visa fler...
Lee, Sang Gyu (författare)
Memorial Sloan-Kettering Cancer Center
Sjöström, Kjell (författare)
Innovagen AB
Gardner, Rui (författare)
Memorial Sloan-Kettering Cancer Center
McDevitt, Michael R. (författare)
Memorial Sloan-Kettering Cancer Center,Weill Cornell Medical College
O'Reilly, Richard (författare)
Memorial Sloan-Kettering Cancer Center,Weill Cornell Medical College
Thorek, Daniel L J (författare)
Johns Hopkins University School of Medicine
Larson, Steven M (författare)
Weill Cornell Medical College,Memorial Sloan-Kettering Cancer Center
Veach, Darren (författare)
Weill Cornell Medical College,Memorial Sloan-Kettering Cancer Center
Ulmert, David (författare)
Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Urologi, Malmö (Abrahamsson),Forskargrupper vid Lunds universitet,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Urological research, Malmö,Lund University Research Groups,Memorial Sloan-Kettering Cancer Center
visa färre...
 (creator_code:org_t)
2017-07-26
2017
Engelska 15 s.
Ingår i: Oncotarget. - : Impact Journals, LLC. - 1949-2553. ; 8:39, s. 65917-65931
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is overexpressed in a broad range of malignancies, while absent in most healthy human tissues, making it an attractive diagnostic cancer biomarker and therapeutic target. Although commonly viewed as an intracellular protein, we have demonstrated that PRAME has a membrane bound form with an external epitope targetable with conventional antibodies. We generated a polyclonal antibody (Membrane associated PRAME Antibody 1, MPA1) against an extracellular peptide sequence of PRAME. Binding of MPA1 to recombinant PRAME was evaluated by Enzyme-Linked Immunosorbent Assay (ELISA). Flow cytometry and confocal immunofluorescence microscopy of MPA1 was performed on multiple tumor cell lines. Reverse Transcription Polymerase Chain Reaction (RTPCR) for PRAME was conducted to compare protein and transcriptional expression levels. We demonstrated a robust proof-of-concept for PRAME targeting in vivo by radiolabeling MPA1 with zirconium-89 (89Zr-DFO-MPA1) and demonstrating high specific uptake in PRAME expressing tumors. To our knowledge, this is the first time a cancer testis antigen has been targeted using conventional antibody technologies. Thus, PRAME can be exploited for multiple clinical applications, including targeted therapy, diagnostic imaging and treatment guidance in a widerange of malignancies, with minimal off-target toxicity.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Nyckelord

Cancer
Immuno-targeting
Noninvasive imaging
PRAME
Targeted therapy

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy